BioLife Solutions, Inc. (BLFS): Price and Financial Metrics
BioLife Solutions, Inc. (BLFS)
Today's Latest Price: $28.58 USD
Updated Oct 22 4:00pm
Add BLFS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BLFS Stock Summary
- BLFS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 555.27 -- higher than 93.62% of US-listed equities with positive expected earnings growth.
- Price to trailing twelve month operating cash flow for BLFS is currently 179.31, higher than 97.93% of US stocks with positive operating cash flow.
- BLFS's price/sales ratio is 24.36; that's higher than the P/S ratio of 93.27% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Biolife Solutions Inc are LLNW, XXII, EPAY, PD, and CNTG.
- Visit BLFS's SEC page to see the company's official filings. To visit the company's web site, go to www.biolifesolutions.com.
BLFS Stock Price Chart Interactive Chart >
BLFS Price/Volume Stats
| Current price | $28.58 | 52-week high | $30.27 |
| Prev. close | $28.15 | 52-week low | $7.37 |
| Day low | $28.04 | Volume | 144,500 |
| Day high | $28.89 | Avg. volume | 260,535 |
| 50-day MA | $25.01 | Dividend yield | N/A |
| 200-day MA | $17.39 | Market Cap | 914.62M |
BioLife Solutions, Inc. (BLFS) Company Bio
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company was founded in 1987 and is based in Bothell, Washington.
BLFS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $28.58 | $3.35 | -89% |
Below please find a table outlining a discounted cash flow forecast for BLFS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Biolife Solutions Inc ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 88.5%. As for the metrics that stood out in our discounted cash flow analysis of Biolife Solutions Inc, consider:
- As a business, BLFS is generating more cash flow than merely 6.57% of positive cash flow stocks in the Healthcare.
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.09% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Biolife Solutions Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -1,238.5. This coverage rate is greater than that of merely 0.46% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -89% |
| 1% | -89% |
| 2% | -89% |
| 3% | -88% |
| 4% | -88% |
| 5% | -88% |
Want more companies with a valuation profile/forecast similar to that of Biolife Solutions Inc? See LGND, ELAN, PCRX, RGEN, and TEVA.
Loading social stream, please wait...